Frequency of c-MPL and JAK2V617F Mutations in Iranian Patients with Philadelphia-Negative Myeloproliferative Disorders and its Association with Clinical and Laboratory Findings

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Hematology, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran

2 Associate Professor, Department of Hematology, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran

3 Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Myeloproliferative disorders are a group of diseases characterized by increased proliferation of myeloid lineage. In addition to JAK2V617F mutation, several mutations in the c-MPL gene were described in patients with Philadelphia-negative Chronic Myeloproliferative disorders (Ph-negative MPNs) that could be important in the pathogenesis of diseases. The aim of the present study was to investigate the frequency of c-MPL and JAK2V617F mutations in Iranian patients with Philadelphia-negative Myeloproliferative disorders.Methods: Peripheral blood samples from 60 patients with Philadelphia-negative Myeloproliferative disorders, subgroups of essential thrombocythemia (ET) and primary myelofibrosis (PMF) and 25 healthy subjects, as control, were taken. In order to investigate the mutation status of c-MPL and Jak2 V617F via using sequencing, the amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) and allele specific-polymerase chain reaction (AS-PCR) were used.Findings: Of the total of 60 patients, 34 (56.6%) and 1 (1.7%) had Jak2V617F and c-MPL mutations, respectively. Patients with Jak2V617F mutation had higher white blood cell (WBC) counts (P = 0.005) and hemoglobin concentrations than those without the mutation (P = 0.003). In addition, for all healthy subjects in control group, mutation was negative.Conclusion: The present study revealed that the c-MPL mutations, unlike the Jak2V617F mutations, are rare in Iranian patients with Philadelphia-negative Chronic Myeloproliferative disorders and the low mutation rate should be considered in the design of screening strategies of patients with myeloproliferative disorders.

Keywords

References

  1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355(23): 2452-66.
  2. Michiels JJ, Bernema Z, Van BD, De RH, Schroyens W. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). Pathol Biol (Paris) 2007; 55(2): 92-104.
  3. Panani AD. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications. Cancer Lett 2007; 255(1): 12-25.
  4. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005; 11(12): 546-54.
  5. Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 2008; 22(10): 1813-7.
  6. Panani AD. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications. Cancer Lett 2009; 284(1): 7-14.
  7. Pecquet C, Staerk J, Chaligne R, Goss V, Lee KA, Zhang X, et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood 2010; 115(5): 1037-48.
  8. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108(10): 3472-6.
  9. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112(1): 141-9.
  10. Karimzadeh P, Ghaffari SH, Chahardouli B, Zaghal A, Einollahi N, Mousavi SA, et al. Evaluation of JAK2V617F mutation prevalence in myeloproliferative neoplasm by AS-RT-PCR. Iran J Pediatr Hematol Oncol 2011; 1(2): 38-42.
  11. Zhuge J, Zhang W, Zhang W, Xu M, Hoffman R. Sensitive detection of MPLW515L/K mutations by amplification refractory mutation system (ARMS)-PCR. Clin Chim Acta 2010; 411(1-2): 122-3.
  12. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3(7): e270.
  13. Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 2008; 22(8): 1557-66.
  14. Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008; 112(3): 844-7.
  15. Hu WY, Zhao Y, Ishii T, Sozer S, Shi J, Zhang W, et al. Haematopoietic cell lineage distribution of MPLW515L/K mutations in patients with idiopathic myelofibrosis. Br J Haematol 2007; 137(4): 378-9.
  16. Lieu CH, Shen YJ, Lai WC, Tsai WH, Hsu HC. Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms. J Chin Med Assoc 2010; 73(10): 530-2.
  17. Asghari A, Shahriari Ahmadi A, Basi A, Vakili M, Razavi M, Arabi M, et al. The association between prevalence of JAK2V617F mutation and blood indicies in groups of patients with myeloproliferative neoplasms in Rasul Akram Hospital. Int J Hematol Oncol Stem Cell Res 2011; 5(4): 10-3.
Journal of Isfahan Medical School
Volume 32, Issue 301 - Serial Number 301
July and August 2014
Pages 1487-1495

Files

History

  • Receive Date: 04 August 2014
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics